Discovery & Overview
How a fragment of human gastric juice became one of the most studied healing peptides in animal research
The Body Protection Compound
In 1991, a research team at the University of Zagreb led by Professor Predrag Sikiric isolated a peptide fragment from human gastric juice that would become one of the most debated compounds in peptide research. They named it BPC-157 -- Body Protection Compound-157 -- and over the next three decades, it would be tested in hundreds of animal studies across nearly every tissue type in the body.
BPC-157 is a pentadecapeptide: a chain of exactly 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a larger protein found naturally in human gastric juice. Despite over 100 published animal studies showing tissue repair effects, it has zero completed randomized human clinical trials -- making it one of the most popular yet least proven peptides in existence.
Gastric Origins
BPC-157 is not synthetic in concept -- it is a partial sequence of a protein that your body already produces in gastric juice.
The larger protein BPC (Body Protection Compound) is found in human gastric juice and appears to play a role in the stomach's natural ability to protect and repair its own lining. Sikiric's team isolated a 15-amino-acid fragment that retained the protective properties of the full protein -- and could be synthesized in a lab.
What made BPC-157 immediately interesting was its stability. Most peptides are rapidly degraded by stomach acid and digestive enzymes. BPC-157, perhaps because it evolved in gastric juice, survives these conditions remarkably well. This gave it a property almost no other peptide has: oral bioavailability.
The 15-Amino-Acid Sequence
Each residue in BPC-157's compact chain plays a specific role in its stability and biological activity.
the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val has several notable features:
proline-rich region (positions 3-5, 8): four of the 15 residues are proline, which creates rigid kinks in the peptide chain. this rigidity contributes to BPC-157's resistance to enzymatic degradation -- proteases struggle to cleave at proline-containing bonds.
charged residues (Glu, Lys, Asp, Asp): the mix of positive (Lys) and negative (Glu, Asp, Asp) charges creates electrostatic interactions that likely contribute to receptor binding and protein-protein interactions.
hydrophobic tail (Leu, Val): the C-terminal leucine and valine residues provide a hydrophobic anchor that may be important for membrane interactions and tissue penetration.
Research Timeline
Three decades of animal research, from gastric protection to whole-body tissue repair.
1991-1999: gastric origins. the earliest studies focused on BPC-157's natural role -- protecting the stomach lining. Sikiric's team showed it could prevent and heal gastric ulcers caused by NSAIDs, alcohol, and stress in rats.
2000-2009: musculoskeletal expansion. researchers expanded into tendons, ligaments, and muscle. studies in rats showed accelerated healing of transected Achilles tendons, crushed muscles, and damaged ligaments.
2010-2019: neuroprotection and mechanisms. the scope widened to include traumatic brain injury, dopamine system modulation, and peripheral nerve repair. mechanistic studies identified the nitric oxide and growth factor pathways.
2020-present: explosion of interest. social media and biohacking communities drove massive consumer demand, despite the persistent absence of human clinical trials. the FDA placed BPC-157 on its "do not compound" list in 2023.
The Animal Evidence
A broad overview of what animal studies have shown -- and the critical gap where human data should be.
BPC-157 has been studied in animal models for an unusually wide range of conditions:
gut protection: NSAID-induced ulcers, alcohol-induced damage, inflammatory bowel disease models, intestinal anastomosis healing, and esophageal lesions.
musculoskeletal: Achilles tendon transection, medial collateral ligament rupture, quadriceps muscle crush injury, and bone fracture healing.
wound healing: skin incisions, burn wounds, corneal injuries, and surgical wound complications.
neuroprotection: traumatic brain injury, dopaminergic system damage (methamphetamine, haloperidol models), peripheral nerve transection, and spinal cord injury.
What's Ahead
This is unit 1 of a 12-unit mastery course covering everything known about BPC-157.
in the units ahead, you'll learn the molecular structure behind BPC-157's unusual stability, how its mechanisms (angiogenesis, nitric oxide, growth factors) work at the cellular level, detailed research across every tissue type (gut, tendons, wounds, brain), administration and bioavailability differences, safety concerns and quality risks, and how to critically evaluate the evidence landscape.
every claim is traced back to its primary research source, and every limitation is clearly stated. this course is designed to give you the knowledge to evaluate BPC-157 claims critically -- not to promote its use.
Knowledge Check
Test what you've learned about BPC-157's origins and research landscape.
Practice Exercises
Reinforce your understanding with interactive exercises.